180 related articles for article (PubMed ID: 18025151)
1. IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes.
Marzec M; Liu X; Kasprzycka M; Witkiewicz A; Raghunath PN; El-Salem M; Robertson E; Odum N; Wasik MA
Blood; 2008 Feb; 111(4):2181-9. PubMed ID: 18025151
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.
Marzec M; Liu X; Wysocka M; Rook AH; Odum N; Wasik MA
PLoS One; 2011; 6(9):e24849. PubMed ID: 21949767
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells.
Marzec M; Halasa K; Kasprzycka M; Wysocka M; Liu X; Tobias JW; Baldwin D; Zhang Q; Odum N; Rook AH; Wasik MA
Cancer Res; 2008 Feb; 68(4):1083-91. PubMed ID: 18281483
[TBL] [Abstract][Full Text] [Related]
4. Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes.
Kasprzycka M; Zhang Q; Witkiewicz A; Marzec M; Potoczek M; Liu X; Wang HY; Milone M; Basu S; Mauger J; Choi JK; Abrams JT; Hou JS; Rook AH; Vonderheid E; Woetmann A; Odum N; Wasik MA
J Immunol; 2008 Aug; 181(4):2506-12. PubMed ID: 18684941
[TBL] [Abstract][Full Text] [Related]
5. JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells.
Yamada O; Ozaki K; Akiyama M; Kawauchi K
Mol Cancer Ther; 2012 May; 11(5):1112-21. PubMed ID: 22402124
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
7. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
[TBL] [Abstract][Full Text] [Related]
8. The ERK1/2 and mTORC1 Signaling Pathways Are Involved in the Muscarinic Acetylcholine Receptor-Mediated Proliferation of SNU-407 Colon Cancer Cells.
Park YS; Liu Z; Vasamsetti BM; Cho NJ
J Cell Biochem; 2016 Dec; 117(12):2854-2863. PubMed ID: 27167250
[TBL] [Abstract][Full Text] [Related]
9. Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells.
Ma Z; Zhu L; Luo X; Zhai S; Li P; Wang X
Cancer Biol Ther; 2012 Sep; 13(11):1009-17. PubMed ID: 22825337
[TBL] [Abstract][Full Text] [Related]
10. mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A.
Harwood FC; Shu L; Houghton PJ
J Biol Chem; 2008 Feb; 283(5):2575-85. PubMed ID: 18056704
[TBL] [Abstract][Full Text] [Related]
11. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
12. Peptide combinatorial libraries identify TSC2 as a death-associated protein kinase (DAPK) death domain-binding protein and reveal a stimulatory role for DAPK in mTORC1 signaling.
Stevens C; Lin Y; Harrison B; Burch L; Ridgway RA; Sansom O; Hupp T
J Biol Chem; 2009 Jan; 284(1):334-344. PubMed ID: 18974095
[TBL] [Abstract][Full Text] [Related]
13. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
14. Activation and function of the mTORC1 pathway in mast cells.
Kim MS; Kuehn HS; Metcalfe DD; Gilfillan AM
J Immunol; 2008 Apr; 180(7):4586-95. PubMed ID: 18354181
[TBL] [Abstract][Full Text] [Related]
15. Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes.
Veilleux A; Houde VP; Bellmann K; Marette A
Mol Endocrinol; 2010 Apr; 24(4):766-78. PubMed ID: 20203102
[TBL] [Abstract][Full Text] [Related]
16. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.
López-Lago MA; Okada T; Murillo MM; Socci N; Giancotti FG
Mol Cell Biol; 2009 Aug; 29(15):4235-49. PubMed ID: 19451229
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.
Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN
J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
[TBL] [Abstract][Full Text] [Related]
19. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
20. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]